eLearning module: Why do we need biosimilars?
This expert-authored eLearning module focuses on explaining why we need biosimilars, in particular from an economic point of view. This module also provides a brief overview of biosimilars’ historical background.
This module will take up to 20 minutes to complete.
Learning objectives
On completion of the eLearning module, you will be able to:
- Explain what biosimilar products are, distinguishing the main differences between these generic medicines.
- Understand the importance of developing biosimilar products and what impact they may have on access to oncology treatment.
Target audience
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.
r Huub Schellekens MD, PhD is emeritus professor of Pharmaceutical Biotechnology at Utrecht University in the Netherlands. He studied medicine at Erasmus University in Rotterdam, The Netherlands ( 1967-1973), where he also did his training in Medical Microbiology (1976-1980) and received his PhD. in 1980.